MedTrace Logo

Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis

NCT02722811 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-04-22

No results posted yet for this study

Summary

Primary aim: evaluate efficacy of subcutaneous injection of etanercept for moderate and severe knee osteoarthritis.

Second aim: investigate the potentiality of serum cytokines (TNF-α, Interleukin 1-α (IL1-α), IL1-β, matrix metalloproteinases1 (MMP1), MMP13) to predict the response of subcutaneous injection of etanercept for moderate and severe knee osteoarthritis.

Conditions

  • Osteoarthritis Of Knee

Interventions

DRUG

Etanercept

etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks

OTHER

Health education, exercise and diet guidance

Health education, exercise and diet guidance in patient; treatment: 8 weeks

Sponsors & Collaborators

  • Shanghai Baiying Medical Technology Co., Ltd.

    collaborator INDUSTRY

  • First Affiliated Hospital of Harbin Medical University

    lead OTHER

Principal Investigators

  • Zhiyi Zhang, Ph.D · First Affiliated Hospital of Harbin Medical University

  • Yifang Mei, M.D · First Affiliated Hospital of Harbin Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-07-31
Completion
2017-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02722811 on ClinicalTrials.gov